Ranibizumab-eqrn, a biosilimar by Coherus BioSciences, exceeds 100,000 doses in first year

(Image Credit: ©Prasanth - Adobe.Stock.com)

Coherus BioSciences, Inc. announced in a press release¹ that sales of their biosimilar ranibizumab-eqrn (CIMERLI) to retinal specialists has exceeded 100,000 doses in its first year, having launched commercially on October 3, 2022.

Paul Reider, Chief Commercial Officer of Coherus shared why this milestone is an important marker for the company and the retinal community. In the press release¹, he said, “eclipsing 100,000 doses sold to retinal specialists within the first full year after commercial launch is an important milestone for CIMERLI and reinforces the retinal community’s desire for a safe and effective biosimilar option to LUCENTIS. Achieving 25% market share speaks to the strength of our commercial capabilities and replicates the success we saw with UDENYCA in its first year on the market. We look forward to potential continued sales growth for CIMERLI as more accounts continue their conversion.”

Similarly, Denny Lanfear, Chairman and Chief Executive Officer of Coherus, also noted the company’s growth over the past year and shared hope for their ability to provide additional treatment solutions to ophthalmologists and their patients. He said, “over the past 12 months we have launched 3 new products: CIMERLI, the UDENYCA auto-injector and YUSIMRY.”¹

Coherus plans to report CIMERLI® net sales for the third quarter when the company reports Q3 2023 financial results in November.

Reference:

1. CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch. Coherus BioSciences, Inc. October 4, 2023. Accessed October 17, 2023. https://www.globenewswire.com/news-release/2023/10/04/2754586/33333/en/CIMERLI-ranibizumab-eqrn-Sales-Exceed-100-000-Doses-in-First-Year-of-Launch.html